Update on cardio-oncology: Novel cancer therapeutics and associated cardiotoxicities

Avirup Guha, Merna Armanious, Michael G. Fradley

Research output: Contribution to journalArticlepeer-review

32 Scopus citations

Abstract

There have been significant advances in the field of oncology leading to improved survival as a result of novel targeted and immunotherapies. Despite these improved outcomes, there is increased recognition of cardiotoxicities associated with these therapies that can lead to significant morbidity and mortality. As such, the field of cardio-oncology has seen significant growth over the last several years. In this review, we discuss recent advances in the field of cardio-oncology and provide a detailed discussion of the cardiovascular complications associated with novel cancer therapeutics including tyrosine kinase inhibitors, proteasome inhibitors, histone deacetylase inhibitors, CDK4/6 inhibitors and immunotherapies.
Original languageEnglish (US)
Pages (from-to)29-39
Number of pages11
JournalTrends in Cardiovascular Medicine
Volume29
Issue number1
DOIs
StatePublished - Jan 1 2019

Keywords

  • Cardio-oncology
  • Cardiotoxicity
  • Proteasome inhibitors
  • Tyrosine kinase inhibitors

Fingerprint

Dive into the research topics of 'Update on cardio-oncology: Novel cancer therapeutics and associated cardiotoxicities'. Together they form a unique fingerprint.

Cite this